DURHAM, NC: October, 2008

ENTHALPY’S SINGLE POINT OF CONTACT POLICY SUPPORTS SMOOTH GROWTH IN BIOANALYTICAL SERVICES – Sponsors acclaim convenient access to project managers and information.

Enthalpy Analytical, Inc., a growing mid-sized bioanalytical laboratory in Durham, NC has a unique business model that allows the company to consistently outshine its competition.

One novel aspect of Enthalpy’s operation is that every client is assigned an experienced scientist as a single point of contact within the company. These scientists manage projects and are committed to keeping sponsors updated with relevant information.

Enthalpy’s scientists are experienced analytical chemists with substantial credentials. The company’s project management team includes Lisa Ford, PhD in bio-organic chemistry from Duke University with more than seven years of bioanalytical experience and Kendall Powell, a Duke chemistry PhD. Prior to joining Enthalpy, Powell performed LC/MS small-molecule research in metabolomics. Recently appointed scientist Craig Sykes holds a Master’s degree in analytical chemistry from UNC at Chapel Hill.

In addition to the single point of contact approach, Enthalpy operates a distinct business strategy, called The 70% Solution. This approach keeps scheduled projects at 70% of lab capacity in order to provide consistent availability for quick turnaround projects without compromising the company’s primary commitment: producing correct results that are on time or ahead of schedule.

The 70% Solution also includes investment in leading-edge technologies, including 9 blue chip Sciex API 4000 and 5000 LC/MS/MS units and Hamilton MicroStar automated liquid handling systems.

ABOUT ENTHALPY ANALYTICAL, INC.

Privately owned, Enthalpy Analytical was founded in 1993 to meet the marketplace need for fast, reliable analytical services. Enthalpy was the first lab in the Research Triangle to deploy the API 5000™. Enthalpy’s GLP-compliant LC/MS/MS Bioanalytical Division provides critical bioanalytical support at every stage of drug discovery and development.